Quadrature Capital’s Cardlytics CDLX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-1,995
Closed -$36.3K 1091
2025
Q1
$36.3K Buy
1,995
+326
+20% +$9.31K ﹤0.01% 997
2024
Q4
$62.1K Sell
1,669
-296
-15% -$11.3K ﹤0.01% 948
2024
Q3
$62.9K Buy
+1,965
New +$109K ﹤0.01% 898
2024
Q2
Sell
-13,162
Closed -$1.91M 1169
2024
Q1
$1.91M Buy
+13,162
New +$1.11M 0.03% 312
2020
Q1
Sell
-2,010
Closed -$1.26M 524
2019
Q4
$1.26M Buy
+2,010
New +$983K 0.05% 257

Other funds holding CDLX

Quadrature Capital's CDLX Position: Q2 2025 in Review

Quadrature Capital sold out of Cardlytics (CDLX) in Q2 2025, closing a stake of 1,995 shares — an estimated $36.3K sold.

Quadrature Capital first reported a position in CDLX in Q4 2019 and held it in 5 quarters. The position peaked at $1.91M in Q1 2024. 89 funds tracked by Wall St. Rank hold CDLX as of Q2 2025.

  • Quadrature Capital reported no remaining Cardlytics position as of Q2 2025 after selling out during the quarter.
  • Quadrature Capital sold 1,995 Cardlytics shares in Q2 2025, an estimated $36.3K.
  • Quadrature Capital first reported a position in Cardlytics in Q4 2019 and held it in 5 quarters.
  • Quadrature Capital's Cardlytics position peaked at $1.91M in Q1 2024.
  • 89 funds tracked by Wall St. Rank held Cardlytics as of Q2 2025.

Based on Quadrature Capital's 13F filing for Q2 2025, filed 13 Aug 2025.